Back

Are there effects of PCSK9 inhibitors beyond cholesterol lowering?

26 August 2017 (12:07 - 12:30)
Organised by:
Congress Presentation Part of: PCSK9 inhibition - cholesterol reduction and beyond Lipids ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Bertrand Cariou

Institut du Thorax, Inserm UMR 1087, Nantes (France)

3 More presentations in this session

Presentation thumbnail
A global view: the rationale for aggresive LDL lowering
Professor S. Nissen (Cleveland, US)
Slides Video
Presentation thumbnail
Cholesterol metabolism and the role of PCSK9
Professor S. Nicholls (Melbourne, AU)
Slides Video
Presentation thumbnail
Show me the data: clinical efficacy, safety and indications of PCSK9 inhibition
Professor J. Jukema (Leiden, NL)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibition - cholesterol reduction and beyond

The Event

Event poster

ESC Congress 2017

26 August 2017 12:07 CET
You may be interested in
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors on coronary plaque: a meta-analysis and trial sequential analysis
1 September 2025
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021
thumbnail
Congress Presentation
GLP1-RA associated with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences
20 June 2025
thumbnail
Congress Presentation
Time course of LDL-C lowering after initiation of PCSK9 inhibition or bempedoic acid in atherosclerotic cardiovascular disease
20 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources